Cowen restated their buy rating on shares of SAGE Therapeutics (NASDAQ:SAGE) in a research report released on Thursday morning, AnalystRatings.com reports. Cowen currently has a $96.00 price objective on the biopharmaceutical company’s stock.
A number of other analysts also recently commented on the company. Stifel Nicolaus restated a buy rating on shares of SAGE Therapeutics in a report on Wednesday, November 20th. Morgan Stanley reiterated a buy rating and issued a $217.00 target price on shares of SAGE Therapeutics in a report on Sunday, November 24th. SunTrust Banks downgraded SAGE Therapeutics from a buy rating to a hold rating and lowered their price target for the company from $210.00 to $70.00 in a research report on Thursday. ValuEngine lowered SAGE Therapeutics from a strong-buy rating to a buy rating in a research note on Monday, November 11th. Finally, Royal Bank of Canada lowered SAGE Therapeutics from an outperform rating to a sector perform rating and set a $73.00 price objective on the stock. in a research note on Thursday. One analyst has rated the stock with a sell rating, six have issued a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the stock. SAGE Therapeutics presently has a consensus rating of Buy and an average target price of $128.81.
Shares of NASDAQ:SAGE opened at $64.46 on Thursday. The company has a market cap of $3.12 billion, a P/E ratio of -7.98 and a beta of 2.52. The company has a quick ratio of 12.67, a current ratio of 12.67 and a debt-to-equity ratio of 0.03. SAGE Therapeutics has a 52 week low of $56.50 and a 52 week high of $193.56. The business has a fifty day simple moving average of $142.30 and a 200-day simple moving average of $160.81.
SAGE Therapeutics (NASDAQ:SAGE) last issued its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($3.48) EPS for the quarter, missing the consensus estimate of ($3.41) by ($0.07). The company had revenue of $3.57 million for the quarter, compared to analyst estimates of $2.52 million. SAGE Therapeutics had a negative return on equity of 60.00% and a negative net margin of 12,931.34%. The business’s revenue for the quarter was up 35600.0% on a year-over-year basis. During the same period last year, the company posted ($2.63) EPS. Sell-side analysts expect that SAGE Therapeutics will post -13.77 earnings per share for the current fiscal year.
Hedge funds and other institutional investors have recently modified their holdings of the company. US Bancorp DE raised its holdings in shares of SAGE Therapeutics by 6.3% during the 2nd quarter. US Bancorp DE now owns 1,122 shares of the biopharmaceutical company’s stock valued at $205,000 after buying an additional 66 shares during the period. Commonwealth Equity Services LLC lifted its position in SAGE Therapeutics by 4.5% during the 2nd quarter. Commonwealth Equity Services LLC now owns 1,772 shares of the biopharmaceutical company’s stock worth $324,000 after acquiring an additional 77 shares in the last quarter. Meadow Creek Investment Management LLC boosted its holdings in SAGE Therapeutics by 4.6% in the 2nd quarter. Meadow Creek Investment Management LLC now owns 1,808 shares of the biopharmaceutical company’s stock worth $331,000 after acquiring an additional 80 shares during the period. Prudential Financial Inc. boosted its holdings in SAGE Therapeutics by 4.2% in the 2nd quarter. Prudential Financial Inc. now owns 2,490 shares of the biopharmaceutical company’s stock worth $456,000 after acquiring an additional 100 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in SAGE Therapeutics by 3.1% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,374 shares of the biopharmaceutical company’s stock worth $473,000 after acquiring an additional 103 shares during the period.
About SAGE Therapeutics
Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone that has completed Phase III clinical trials for the treatment of postpartum depression (PPD).
Read More: Straddles
Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.